BT-062
by Melissa Cobleigh
Published: Oct 4, 2010 10:23 pm
Published: Oct 4, 2010 10:23 pm
| Brand Name: | |
| Generic Name: | |
| Code Name: | BT-062 |
| Company: | Biotest |
| FDA Clinical Phase: | 1/2 |
Description:
BT-062 (news articles) is a toxic drug bound to an antibody that helps deliver the treatment to myeloma and other cancer cells. When the compound enters a cancer cell, it releases the toxic drug that ultimately kills the cell. In a Phase 1 trial, BT-062 demonstrated an acceptable and manageable safety profile as well as evidence of clinical efficacy.
Clinical Trials:
For a list of clinical trials studying BT-062 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Information about BT-062 also is available at the Biotest website.
Related Articles:
- Getting To Know: TNB-383B
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Getting To Know: Tiragolumab
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
